share_log

Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity

Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity

Structure Therapeutics在评估用于肥胖的口服小分子GLP-1受体激动剂GSBR-1290的20亿ACCESS临床研究中给首批患者用药。
Benzinga ·  16:04

Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity

Structure Therapeutics 在 20 期为首批患者剂量 ACCESS 临床研究评估肥胖症患者口服小分子 GLP-1 受体激动剂 GSBR-1290

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发